Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

Drug failures are just a fact of life in pharma, and anytime you see a blue-chip stock like ABBV lose $40 billion in market ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

Disappointing news from the laboratory weighed on AbbVie (NYSE: ABBV) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however, it did not ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating yesterday. David Risinger’s rating is based on several key considerations surrounding ...

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

Shares of AbbVie Inc. ABBV sank 0.24% to $201.20 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 2.53% to 5,929.04 ...

1 Day ABBV -12.40% DJIA 0.79% S&P 500 0.14% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...